Acute Pain News and Research

RSS

Pain can be treated by targeting immune and nerve cells outside brain or spinal cord

The treatment of inflammatory pain can be improved by endogenous opioid peptides acting directly in injured tissue. Scientists at the Charité - Universitätsmedizin Berlin and the Université Paris Descartes showed that pain can be successfully treated by targeting immune and nerve cells outside the brain or spinal cord.

3 Dec 2012

AcelRx commences dosing in ARX-04 sufentanil NanoTab Phase 2 study for acute and breakthrough pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has dosed the first subjects in a Phase 2, placebo-controlled, dose-finding study of its ARX-04 sufentanil NanoTab product candidate.

5 Nov 2012

Hereditary genes responsible for pain severity after motor vehicle collisions

Two studies presented at the ANESTHESIOLOGY 2012 annual meeting found that hereditary genes were responsible for the amount and type of pain experienced after a motor vehicle collision (MVC).

17 Oct 2012

Babies’ facial expressions after jab reveal pain type

Researchers have discerned seven distinct facial expressions in babies immediately after vaccination, which they say could signal different types of pain and aid communication of distress to caregivers.

3 Oct 2012

FDA clears Teleflex’s ARROW FlexBlock continuous peripheral nerve block catheter

Teleflex Incorporated today announced the ARROW FlexBlock continuous peripheral nerve block catheter has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

24 Sep 2012

No evidence for added benefits of spinal manipulation for acute lower back pain

Manipulating or "adjusting" the spine is a popular way to treat occasional or acute lower back pain and is covered by many health insurance plans, but a recent review by The Cochrane Library finds no evidence to suggest it is more effective than other therapy options.

21 Sep 2012

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.

19 Sep 2012

Study evaluates distribution and severity of pain in sexual assault victims

A majority of sexual assault victims experience severe pain in the early aftermath of the crime but less than a third of these victims receive pain medications, according to research in The Journal of Pain, the peer review publication of the American Pain Society.

12 Sep 2012

Predictors for pain after breast cancer surgery unveiled

Researchers have identified that chronic preoperative pain, axillary surgery, and psychologic robustness significantly predict acute pain outcomes after breast cancer surgery.

5 Sep 2012

Unique approaches to improve pain management in hospitals and clinical practices

Five recent Johns Hopkins University School of Nursing DNP graduates have taken different and unique approaches in working to improve the implementation of pain management in hospitals and clinical practices.

1 Sep 2012

AcelRx commences third ARX-01 Phase 3 study in post-operative pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced dosing of the first patient in the third of three planned Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia (PCA) system.

24 Aug 2012

Pain intensity not only predictor for hysterectomy

Presurgical and surgical factors, and postsurgical pain intensity, should be taken into account when providing rescue analgesia to women after hysterectomy, researchers say.

22 Aug 2012

Back pain sufferers show quick response to chiropractic therapy

Patients with low back pain undergoing chiropractic treatment who respond to treatment are likely to improve very quickly, study findings show.

7 Aug 2012

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

31 Jul 2012

Depomed acquires all rights to Zipsor from Xanodyne

Depomed, Inc. today announced that it has acquired all rights to Zipsor (diclofenac potassium) Liquid Filled Capsules from Xanodyne Pharmaceuticals, Inc. Zipsor is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults.

22 Jun 2012

Iroko announces results from diclofenac Phase 3 study on post-surgical pain

Iroko Pharmaceuticals, LLC today announced Phase 3 study results that showed patients treated with the company's novel, submicron particle, lower-dose diclofenac (18mg and 35mg), a non-steroidal anti-inflammatory drug (NSAID), experienced significant pain relief post surgery compared with placebo>0.01 and P<0.001 respectively).

22 Jun 2012

Advances in robotic spine surgery

1. Please could you give a brief outline of robotic spine surgery and its recent history? Robotic spine surgery is very new, less than 10 years old. There are only 10 hospitals in the US offering it and we are the second hospital in California to offer this technology.

15 Jun 2012

UCSF scientists aim to use embryonic stem cells for treatment of neuropathic pain

Chronic pain, by definition, is difficult to manage, but a new study by UCSF scientists shows how a cell therapy might one day be used not only to quell some common types of persistent and difficult-to-treat pain, but also to cure the conditions that give rise to them.

25 May 2012

USPTO issues patent to QRxPharma’s MoxDuo for treatment of acute and chronic pain

QRxPharma Limited announced today that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent No. 8,182,837, which does not expire until 2023.

24 May 2012

Data from Purdue Pharma’s Butrans clinical trials to be presented at APS annual meeting

Purdue Pharma L.P. will present an analysis of data from completed clinical trials for Butrans® (buprenorphine) Transdermal System CIII at the American Pain Society's (APS) 31st Annual Scientific Meeting.

19 May 2012